CHICAGO -- A single infusion of the chimeric antigen receptor (CAR) T-cell therapy ciltacabtagene autoleucel (cilta-cel; ...

In An Exercise in Uncertainty, Jon Gluck traces decades of waiting, watching, enduring experimental treatment, and ...

Yelak Biru was diagnosed with multiple myeloma at 25 and given just a few years to live. Thirty years later, he's thriving.

Johnson & Johnson shared positive ASCO 2025 results, including improved survival and remission in prostate and multiple ...

In a small study, a third of the participants with multiple myeloma, a common blood cancer which has up until now been deemed incurable, seem to have had their cancer disappear, The New York Times ...

In the two decades since a young father was diagnosed with multiple myeloma, clinical trials and advances in treating his ...

Cullinan Therapeutics has reached a deal to exclusively license the rights to the multiple myeloma treatment velinotamig from Genrix Bio. The biopharmaceutical company said Wednesday that velinotamig ...

An innovative blood cancer treatment regime could extend remission by seven months on average ... and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage ...